VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...

George Dudnik, 36, was initially told he had mumps after waking up at 3am with a swollen face in December 2023.

Sino Biopharm has a good financial position. As of December 2024, it has CNY 9.6 billion in cash on hand and CNY 9.6 billion in debt. Total debt outstanding is 14.7% of its total assets. Its capital ...

AnHeart describes taletrectinib as a “next-generation” ROS1 inhibitor that could improve on other drugs in the class, like Pfizer’s first-to-market Xalkori (crizotinib), for example ...

NICE has decided to recommend Rozlytrek after Roche offered a commercially confidential discount on the drug’s list price of £5,160 for 30 days’ supply. ROS1 is a rare mutation found in ...

has approved a New Drug Application (NDA) of DOVBLERON ® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), f NEW YORK, November 26, 2024--Nuvation Bio Inc ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...

In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK ...

We recently published a list of 10 Most Oversold Penny Stocks to Buy According to Analysts. In this article, we are going to ...